ArticleThe Journal of clinical investigation1999
Targeting of functional antibody-CD59 fusion proteins to a cell surface.
Article in The Journal of clinical investigation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 49 citations in OpenAlex.
- Immunogenicity Management Strategies for PEGylated Drug Delivery Systems.International journal of nanomedicine · 2026Review
- Tissue-targeted complement therapeutics.Molecular immunology · 2018Review
- New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.Seminars in immunology · 2016Review
- An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy.The Journal of experimental medicine · 2014Article
- Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.Muscle & nerve · 2012Article
- Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium.PloS one · 2011Article
- Implication of complement system and its regulators in Alzheimer's disease.Current neuropharmacology · 2009Article
- Anticomplement therapy.Biologics : targets & therapy · 2008Article
- Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.The Journal of clinical investigation · 2003Article
- Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.Protein science : a publication of the Protein Society · 2002Article
- Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.Clinical and experimental immunology · 2002Article
- Expression of complement regulating factors in gastric cancer cells.Molecular pathology : MP · 2002Article
- Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.Immunology · 2000Article
- Neuronal death in Alzheimer's disease and therapeutic opportunities.Journal of cellular and molecular medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Complement is involved in the pathogenesis of many diseases, and there is great interest in developing inhibitors of complement for therapeutic application. CD59 is a natural membrane-bound inhibitor of the cytolytic complement membrane attack complex (MAC). In this study, the preparation and characterization of antibody-CD59 (IgG-CD59) chimeric fusion proteins are described. Constructs were composed of soluble CD59 fused to an antibody-combining site at the end of CH1, after the hinge (H), and after CH3 Ig regions. The antigen specificity of each construct was for the hapten 5-dimethylamino-naphthalene-1-sulfonyl (dansyl). Correct folding of each IgG-CD59 fusion partner was indicated by recognition with anti-CD59 antibodies specific for conformational determinants and by IgG-CD59 binding to dansyl. The IgG-CD59 fusion proteins all bound specifically to dansyl-labeled Chinese hamster ovary cells and provided targeted cells, but not untargeted cells, with effective protection from complement-mediated lysis. Data indicate that CD59 must be positioned in close proximity to the site of MAC formation for effective function, and that modes of membrane attachment other than glycophosphatidylinositol linkage can affect CD59 functional activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.